Reif Taylor J, Khabyeh-Hasbani Nathan, Jaime Kayla M, Sheridan Gerard A, Otterburn David M, Rozbruch S Robert
Hospital for Special Surgery, New York, NY.
Weill Cornell Medicine, New York, NY.
JB JS Open Access. 2021 Sep 3;6(3). doi: 10.2106/JBJS.OA.21.00072. eCollection 2021 Jul-Sep.
The use of bone-anchored osseointegration implants for amputation reconstruction continues to expand throughout the world. Benefits are thought to include the elimination of socket-related problems and improved control and proprioception of the prosthetic limb. Reported outcomes have been positive, but skepticism remains with regard to the risk of infection and implant failure. Further results from early adopters are therefore needed prior to widespread acceptance and regulatory approval.
A retrospective review of the first 31 consecutive patients who underwent implantation of a press-fit osseointegration implant of the femur or tibia with follow-up of at least 6 months was performed. The primary outcome was the patient-reported Questionnaire for persons with a Transfemoral Amputation (Q-TFA) measured preoperatively and 6 to 12 months postoperatively. Patient-Reported Outcomes Measurement Information System (PROMIS) and Limb Deformity-Scoliosis Research Society (LD-SRS) scores, 2-minute and 6-minute walk tests, and complications were also recorded.
In this study, 18 femoral reconstructions and 13 tibial reconstructions were performed, with a mean follow-up (and standard deviation) of 21.1 ± 9.2 months. Twenty-eight reconstructions were single-stage implantations. All Q-TFA domains improved significantly (p < 0.001) from preoperatively to postoperatively, including the global score (25.0 ± 17.4 to 81.2 ± 17.6 points), prosthetic use (50.2 ± 39.9 to 91.2 ± 18.7 points), prosthetic mobility (49.7 ± 26.9 to 81.4 ± 21.5 points), and prosthetic problems (46.4 ± 17.5 to 9.1 ± 6.6 points). The overall and functional outcome domains of the PROMIS and LD-SRS and the 2-minute walk test (243 ± 107 to 369 ± 151 ft [74 ± 33 to 112 ± 46 m]; p = 0.022) and 6-minute walk test (609 ± 323 to 1,054 ± 555 ft [186 ± 98 to 321 ± 169 m]; p = 0.016) also improved significantly. Serious adverse events included 2 periprosthetic hip fractures, 1 explantation for septic loosening, and 1 explantation for aseptic loosening, with an overall implant retention of 93%. The most common complication was low-grade, soft-tissue infection requiring oral antibiotics.
Similar to the early experience of other international centers, osseointegration implants improved the overall and functional experience of patients compared with socket prosthetics. Complications were present but manageable and were not a deterrent to ongoing support of the technology.
Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.
骨锚式骨整合植入物用于截肢重建在全球范围内的应用持续增加。其优势被认为包括消除与接受腔相关的问题以及改善假肢的控制和本体感觉。报告的结果是积极的,但对于感染风险和植入物失败仍存在疑虑。因此,在广泛接受和监管批准之前,需要早期使用者提供更多的结果。
对连续31例接受股骨或胫骨压配式骨整合植入物且随访至少6个月的患者进行回顾性研究。主要结局指标是患者报告的术前及术后6至12个月的经股截肢患者问卷(Q-TFA)。还记录了患者报告结局测量信息系统(PROMIS)和肢体畸形-脊柱侧弯研究学会(LD-SRS)评分、2分钟和6分钟步行试验以及并发症。
本研究共进行了18例股骨重建和13例胫骨重建,平均随访时间(及标准差)为21.1±9.2个月。28例重建为单阶段植入。从术前到术后,所有Q-TFA领域均有显著改善(p<0.001),包括总体评分(从25.0±17.4分提高到81.2±17.6分)、假肢使用(从50.2±39.9分提高到91.2±18.7分)、假肢活动度(从49.7±26.9分提高到81.4±21.5分)和假肢问题(从46.4±17.5分提高到9.1±6.6分)。PROMIS和LD-SRS的总体及功能结局领域以及2分钟步行试验(从243±107英尺[74±33米]提高到369±151英尺[112±46米];p=0.022)和6分钟步行试验(从609±323英尺[186±98米]提高到1,054±555英尺[321±169米];p=0.016)也有显著改善。严重不良事件包括2例假体周围髋关节骨折、1例因感染性松动取出植入物和1例因无菌性松动取出植入物,总体植入物保留率为93%。最常见的并发症是轻度软组织感染,需要口服抗生素治疗。
与其他国际中心的早期经验相似,与接受腔假肢相比,骨整合植入物改善了患者的总体和功能体验。并发症虽然存在但可控,并不妨碍对该技术的持续支持。
治疗性IV级。有关证据水平的完整描述,请参阅作者指南。